Advertisement

Symptoms and Impacts in Metastatic Castration-Resistant Prostate Cancer: Qualitative Findings from Patient and Physician Interviews

  • Stefan Holmstrom
  • Shevani Naidoo
  • James Turnbull
  • Emily Hawryluk
  • Jean Paty
  • Robert Morlock
Original Research Article

Abstract

Background

There is little information available on health-related quality of life in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer. This study aimed to develop a conceptual model that describes patients’ experiences of living with this condition.

Methods

This was a cross-sectional, non-interventional qualitative research study. Sixty-minute semi-structured interviews were conducted with physicians experienced in treating metastatic castration-resistant prostate cancer and with chemotherapy-naïve patients with metastatic castration-resistant prostate cancer. Interviews were audio-recorded and transcripts were analysed to identify the key symptoms and impacts on quality of life. Results were used to expand a previously published conceptual model for non-metastatic castration-resistant prostate cancer.

Results

Three physicians and 19 patients with metastatic castration-resistant prostate cancer were interviewed. Physicians identified several symptoms frequently mentioned by their patients: fatigue, bone pain, anxiety, stress, depression and interference with daily activities. The most salient symptoms emerging from the patient interviews were urinary frequency and urgency, fatigue, pain/stiffness and sexual dysfunction. The most salient impacts were interference with daily activities, frustration, anxiety and sleep problems. Compared with non-metastatic castration-resistant prostate cancer, some symptoms and impacts in metastatic castration-resistant prostate cancer were more common and rated as more disturbing (e.g. fatigue, pain, urinary frequency, interference with daily activities and frustration). New concepts that were added to the non-metastatic castration-resistant prostate cancer model, to more accurately reflect the experiences of patients with metastatic disease, were enlarged breasts, muscle loss/deconditioning, inability to focus/mental slowing, body image perception, interference with work and lack of ambition/motivation.

Conclusions

Chemotherapy-naïve patients with metastatic castration-resistant prostate cancer experience a substantial burden from their condition. Furthermore, as castration-resistant prostate cancer progresses from the non-metastatic stage to the early metastatic (pre-chemotherapy) stage, certain symptoms become more common and disturb patients’ lives to a greater extent. The resulting conceptual model for metastatic castration-resistant prostate cancer highlights areas that are not adequately assessed with current patient-reported outcome instruments.

Notes

Acknowledgements

Medical writing assistance was provided by Jonathan Plumb and Nicola French from Bioscript Medical, and editorial assistance was provided by Lauren Smith and Stephanie Rippon from Complete HealthVizion.

Author contributions

SH, JT, EH and JP contributed to the study design. JT and EH were involved in patient recruitment and data collection. JT, EH, JP and RM provided the data analysis. All authors contributed to the data interpretation. RM was involved in the writing of the manuscript. All of the authors provided critical reviews and approved the final manuscript.

Compliance with Ethical Standards

Funding

The study was funded by Astellas. Medical writing and editorial assistance was funded by Astellas Pharma Inc.

Conflict of interest

Stefan Holmstrom is an employee of Astellas. Shevani Naidoo was an employee of Astellas at the time the research was conducted. James Turnbull is an employee of Pfizer and was an employee of IQVIA at the time the research was conducted. Emily Hawryluk and Jean Paty are employees of IQVIA, which received consulting fees from Astellas. Robert Morlock received personal fees from Astellas during the conduct of the research; he has also received personal fees from Abbot Medical Optics, Ironwood and Genentech outside the submitted work.

Ethics approval

The study and all interview materials were reviewed and approved by the New England Independent Review Board (no. 20160817) and conducted in accordance with the Declaration of Helsinki and the regulations of the US Food and Drug Administration.

Consent to participate

All patients provided informed online consent that was verbally confirmed before the start of the interview. As part of the consent procedure, patients agreed that the results could be presented, provided that individual patient data could not be identified.

References

  1. 1.
    Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends: an update. Cancer Epidemiol Biomarkers Prev. 2016;25(1):16–27.CrossRefPubMedGoogle Scholar
  2. 2.
    Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.CrossRefPubMedGoogle Scholar
  3. 3.
    Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.CrossRefGoogle Scholar
  4. 4.
    National Cancer Institute. Cancer stat tacts: prostate cancer; 2018. https://seer.cancer.gov/statfacts/html/prost.html. Accessed 4 May 2018.
  5. 5.
    Anantharaman A, Small EJ. Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment. Expert Rev Anticancer Ther. 2017;17(7):625–33.CrossRefPubMedGoogle Scholar
  6. 6.
    Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71(4):630–42.CrossRefPubMedGoogle Scholar
  7. 7.
    Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65(11):1180–92.CrossRefGoogle Scholar
  8. 8.
    Moreira DM, Howard LE, Sourbeer KN, Amarasekara HS, Chow LC, Cockrell DC, et al. Predictors of time to metastasis in castration-resistant prostate cancer. Urology. 2016;96:171–6.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Kapoor A, Wu C, Shayegan B, Rybak AP. Contemporary agents in the management of metastatic castration-resistant prostate cancer. Can Urol Assoc J. 2016;10(11–12):E414–23.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, et al. Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology. Eur Urol. 2018.  https://doi.org/10.1016/j.eururo.2018.03.028.CrossRefPubMedGoogle Scholar
  11. 11.
    Beer TM, Miller K, Tombal B, Cella D, Phung Holmstrom S, et al. The association between health-related quality-of-life scores and clinical outcomes in metastatic castration-resistant prostate cancer patients: exploratory analyses of AFFIRM and PREVAIL studies. Eur J Cancer. 2017;87:21–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34(12):1402–18.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    European Medicines Agency. Reflection Paper on the use of patient reported outcome (PRO) measures in oncology studies; 2014. https://www.ema.europa.eu/documents/scientific-guideline/draft-reflection-paper-use-patient-reported-outcome-pro-measures-oncology-studies_en.pdf. Accessed 7 Nov 2018.
  14. 14.
    US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Center for Devices and Radiological Health (CDRH). Guidance for industry. patient-reported outcomes measures: use in medical product development to support labeling claims; 2009. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf. Accessed 27 Jan 2017.
  15. 15.
    van Andel G, Bottomley A, Fosså SD, Efficace F, Coens C, Guerif S, et al. An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer. 2008;44(16):2418–24.CrossRefPubMedGoogle Scholar
  16. 16.
    Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000;56(6):899–905.CrossRefPubMedGoogle Scholar
  17. 17.
    Morgans AK, van Bommel AC, Stowell C, Abrahm JL, Basch E, Bekelman JE, et al. Development of a standardized set of patient-centered outcomes for advanced prostate cancer: an international effort for a unified approach. Eur Urol. 2015;68(5):891–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Nussbaum N, George DJ, Abernethy AP, Dolan CM, Oestreicher N, Flanders S, et al. Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science. Prostate Cancer Prostatic Dis. 2016;19(2):111–21.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Sartor O, Flood E, Beusterien K, Park J, Webb I, MacLean D, et al. Health-related quality of life in advanced prostate cancer and its treatments: biochemical failure and metastatic disease populations. Clin Genitourin Cancer. 2015;13(2):101–12.CrossRefPubMedGoogle Scholar
  20. 20.
    Drummond FJ, Kinnear H, O’Leary E, Donnelly Gavin A, Sharp L. Long-term health-related quality of life of prostate cancer survivors varies by primary treatment. Results from the PiCTure (Prostate Cancer Treatment, your experience) study. J Cancer Surviv. 2015;9(2):361–72.CrossRefPubMedGoogle Scholar
  21. 21.
    Eton DT, Lepore SJ. Prostate cancer and health-related quality of life: a review of the literature. Psychooncology. 2002;11(4):307–26.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Giannakopoulos X, Charalabopoulos K, Charalabopoulos A, Golias C, Peschos D, Sofikitis N. Quality of life survey in patients with advanced prostate cancer. Exp Oncol. 2005;27(1):13–7.PubMedGoogle Scholar
  23. 23.
    Tomaszewski EL, Moise P, Krupnick RN, Downing J, Meyer M, Naidoo S, et al. Symptoms and impacts in non-metastatic castration-resistant prostate cancer: qualitative study findings. Patient. 2017;10(5):567–78.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Taylor F, Reasner DS, Carson RT, Deal LS, Foley C, Iovin R, et al. Development of a symptom-based patient-reported outcome instrument for functional dyspepsia: a preliminary conceptual model and an evaluation of the adequacy of existing instruments. Patient. 2016;9(5):409–18.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Eton DT, Shevrin DH, Beaumont J, Victorson D, Cella D. Constructing a conceptual framework of patient-reported outcomes for metastatic hormone-refractory prostate cancer. Value Health. 2010;13(5):613–23.CrossRefPubMedGoogle Scholar
  26. 26.
    Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, et al. Content validity-establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force Report. Part 1: eliciting concepts for a new PRO instrument. Value Health. 2011;14(8):967–77.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    HealthUnlocked; 2018. https://healthunlocked.com/about. Accessed 16 Oct 2018.
  28. 28.
    Guest G, Bunce A, Johnson L. How many interviews are enough? An experiment with data saturation and variability. Field Methods. 2006;18(1):59–82.CrossRefGoogle Scholar
  29. 29.
    Merseburger AS, Bellmunt J, Jenkins C, Parker C, Fitzpatrick JM. Perspectives on treatment of metastatic castration-resistant prostate cancer. Oncologist. 2013;18(5):558–67.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Sullivan PW, Mulani PM, Fishman M, Sleep D. Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer. Qual Life Res. 2007;16(4):571–5.CrossRefPubMedGoogle Scholar
  31. 31.
    Tombal B. Non-metastatic CRPC and asymptomatic metastatic CRPC: which treatment for which patient? Ann Oncol. 2012;23(Suppl. 10):x251–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.Astellas Pharma Inc.Leidenthe Netherlands
  2. 2.Astellas Pharma Inc.ChertseyUK
  3. 3.IQVIANew YorkUSA
  4. 4.Astellas Pharma Inc.NorthbrookUSA

Personalised recommendations